Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioLineRx Ltd. (BLRX : NSDQ)

• Company Description    Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $2.82 Daily Weekly Monthly 20 Day Moving Average: 20,754 shares Shares Outstanding: 4.37 (millions) Market Capitalization: $12.32 (millions) Beta: 1.55 52 Week High: $4.69 52 Week Low: $2.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.47% -10.14% 12 Week 2.55% -0.26% Year To Date 1.81% -4.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HAMA-AYAN STREET MODI-IN TECHNOLOGY PARK - MODI-IN,L3 7177871 ISR ph: 972-2548-9100 fax: 972-8642-9101 ir@biolinerx.com http://www.biolinerx.com

• General Corporate Information    Officers Philip A. Serlin - Chief Executive Officer Aharon Schwartz - Chairman Mali Zeevi - Chief Financial Officer Raphael Hofstein - Director B.J. Bormann - Director Peer Information BioLineRx Ltd. (GSAC) BioLineRx Ltd. (CASIF) BioLineRx Ltd. (ALCD.) BioLineRx Ltd. (OMNN) BioLineRx Ltd. (CGPI.) BioLineRx Ltd. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 09071M304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 4.37 Most Recent Split Date: 1.00 (0.03:1) Beta: 1.55 Market Capitalization: $12.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.59 Price/Cash Flow: - Price / Sales: 8.79 EPS Growth vs. Year Ago Period: -125.90% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: 87.06% vs. Previous Quarter: 145.88% ROE 06/30/26 - - 03/31/26 - -37.73 12/31/25 - -5.61 ROA 06/30/26 - - 03/31/26 - -19.42 12/31/25 - -2.81 Current Ratio 06/30/26 - - 03/31/26 - 1.58 12/31/25 - 1.95 Quick Ratio 06/30/26 - - 03/31/26 - 1.43 12/31/25 - 1.78 Operating Margin 06/30/26 - - 03/31/26 - -563.70 12/31/25 - -99.58 Net Margin 06/30/26 - - 03/31/26 - -563.70 12/31/25 - -99.58 Pre-Tax Margin 06/30/26 - - 03/31/26 - -694.79 12/31/25 - -171.70 Book Value 06/30/26 - - 03/31/26 - 4.79 12/31/25 - 5.36 Inventory Turnover 06/30/26 - - 03/31/26 - 0.12 12/31/25 - 0.09 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.16 12/31/25 - 0.19 Debt-to-Capital 06/30/26 - - 03/31/26 - 13.88 12/31/25 - 16.04

Powered by Zacks Investment Research ©